USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: RADIX THERAPEUTICS, LLC
City: DICKINSON
State: TX
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $497,083.00 2
STTR Phase I $300,000.00 1

Award List:

TP508:A New Drug for Mitigating Lethal Effects of Radiation Exposure

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Barbara M. Olszewskapazdrak
Award Amount: $297,326.00
Abstract:
DESCRIPTION (provided by applicant): With increasing risk of nuclear detonation there is a need for effective medicinal counter-measures that can be delivered after exposure to prevent radiation-induced mortality. Adding to this need, mortality increases s ignificantly when radiation is combined… More

Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
Principal Investigator: Randall M. Goldblum – 409-772-1750
Award Amount: $300,000.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Up to 30% of the US population are now affected by nasal allergy, resulting in a total (direct and indirect) cost of approximately 14.6 billion per year. Seasonal allergic rhinitis (AR), due to exposure to airborne pollen and molds is a major component of this… More

TAS::75 0849::TAS

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Barbara Olszewska-pazdrak – 281-352-5249
Award Amount: $199,757.00
Abstract:
Over 60% of cancer patients are treated with radiotherapy, yet radiation-induced normal tissue damage can cause organ dysfunction and morbidity. Radiotherapy of CNS tumors is problematic due to potential for diminished neurological function or mental retardation. Our proprietary thrombin-derived… More